Abushehab Abdallah, Tunaboylu Mehmet Furkan, Kuruoglu Doga, Meira Pazelli Alexandre, Hussein Sara M, Sharaf Basel A
From the Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, MN.
Plast Reconstr Surg Glob Open. 2024 Dec 19;12(12):e6407. doi: 10.1097/GOX.0000000000006407. eCollection 2024 Dec.
Venous thromboembolism (VTE) poses a major risk after abdominal contouring surgery, impacting morbidity and mortality. Despite various preventative strategies, surgeons are cautious about using enoxaparin for extended postoperative periods. This study aims to determine if a 7-day postoperative course of enoxaparin increases bleeding risks compared with a single dose of intraoperative unfractionated heparin in patients undergoing abdominal contouring surgery.
A retrospective cohort analysis was performed on patients who underwent abdominoplasty or panniculectomy from August 2017 to October 2023. Patients were split into 2 groups: Group 1 received 5000 units of intraoperative unfractionated heparin in addition to 7 days of postoperative enoxaparin (40 mg daily); group 2 received only the intraoperative heparin dose. Primary outcomes included bleeding events and VTE incidence. Secondary outcomes were seroma, infection, surgical site dehiscence, necrosis, drain duration, and reoperation rates.
The study included 121 patients (111 women, 10 men), with 61 patients in group 1 and 60 in group 2. The average age was 49 ± 12 years, and the average body mass index was 29.8 ± 5 kg/m². No cases of VTE were reported. Postoperative bleeding occurred in 3 patients (4.9%) in group I and 2 patients (3.3%) in group 2, showing no statistically significant difference ( = 0.66). Secondary outcomes also showed no significant differences between the groups.
Our study of 121 patients undergoing either abdominoplasty or panniculectomy demonstrated that administering enoxaparin for 7 days postoperatively is safe and does not increase the risk of bleeding.
腹部塑形手术后静脉血栓栓塞(VTE)构成重大风险,影响发病率和死亡率。尽管有各种预防策略,但外科医生对于术后长期使用依诺肝素仍持谨慎态度。本研究旨在确定在接受腹部塑形手术的患者中,与术中单次使用普通肝素相比,术后7天的依诺肝素疗程是否会增加出血风险。
对2017年8月至2023年10月期间接受腹壁成形术或腹部皮肤切除术的患者进行回顾性队列分析。患者分为两组:第1组在术中接受5000单位普通肝素,术后还接受7天依诺肝素(每日40毫克);第2组仅接受术中肝素剂量。主要结局包括出血事件和VTE发生率。次要结局为血清肿、感染、手术部位裂开、坏死、引流持续时间和再次手术率。
该研究纳入121例患者(111例女性,10例男性),第1组61例,第2组60例。平均年龄为49±12岁,平均体重指数为29.8±5kg/m²。未报告VTE病例。第1组有3例患者(4.9%)发生术后出血,第2组有2例患者(3.3%)发生术后出血,差异无统计学意义(P=0.66)。次要结局在两组之间也无显著差异。
我们对121例接受腹壁成形术或腹部皮肤切除术患者的研究表明,术后给予7天依诺肝素是安全的,不会增加出血风险。